Abstract:Aim: Drug innovation is strongly driven by economic incentives. How these incentives work in determining or changing the level of activity of innovators and the direction of their innovation remains understudied. We seek to address these issues in reviewing recent literature on drug innovation, which offers one major unifying theme of pharmacoeconomic scholarship presented at the 2019 AEA-ASSA annual convention.Methods: Drawn from three AEA-ASSA convention panel sessions, papers were reviewed for newly charted research terrains and new research trajectories, and their theoretical and practical implications on efficiency, effectiveness, and value in the production and utilization of pharmaceutical products.Results: While high and continuously rising drug prices are typically claimed as the price of scientific innovation, the reviewed literature finds that this link only partially accounts for the problem. High risk aversion owing to information asymmetries and vastly intractable uncertainties is prevalent among innovating firms. Predatory business models abound. Reverse predatory strategies also exist to maintain product exclusivity without much added clinical benefits, and to constrain generic competition. CEO compensation practices contribute to rising drug prices. Finally, the US government's hands-off policy on drug list prices leave the forces of supply and demand to allocate them and reward innovation (at times perversely), even as the government extensively regulates or over-regulates practically every other aspect of innovation.Conclusions: Price-elasticity of demand is critical in drug innovation. The drug value chain is price-sensitive to the balance of incentives and disincentives to innovation. American health policy should consider charting a middle course that introduces some form of regulatory price control, while stimulating and sustaining the benefits of market competition. That should incentivize stakeholders to take into account both resources and value for money in making decisions based on best-quality, clinical-economic evidence.

Market entry, power, pharmacokinetics: what makes a successful drug innovation?

Market entry, power, pharmacokinetics: what makes a successful drug innovation?

An Improved Approach To Measuring Drug Innovation Finds Steady Rates Of First-In-Class Pharmaceuticals, 1987–2011

A story of breakthrough versus incremental innovation: corporate entrepreneurship in the global pharmaceutical industry

Determinants of radical drug innovation: a systematic literature review

Do current radical innovation measures actually measure radical drug innovation?

Drug Approval Decision Times, International Reference Pricing and Strategic Launches of New Drugs

The impact of external innovation on new drug approvals: A retrospective analysis

The Effect of Government Policy on Pharmaceutical Drug Innovation

Drug discovery in the next decade: innovation needed ASAP

Innovation in high risk drug therapy

Increased contribution of small companies to late-entry drugs: a changing trend in FDA-approved drugs during the 2020s

Newly Developed Prodrugs and Prodrugs in Development; an Insight of the Recent Years

How Pharmaceutical Innovation Evolves: the Path from Science to Technological Development to Marketable Drugs

Drug Repurposing: A Leading Strategy for New Threats and Targets

Can old drugs learn new tricks? Achieving registration and public subsidy listing for off-patent medicines with novel therapeutic applications

Critical Factors Shaping Strategy Development of an Innovative Medicine in Oncology

New Class of Drug: Innovation and Opportunity

Entering the era of computationally driven drug development

Market Share Rewards to Pioneering Brands: An Empirical Analysis and Strategic Implications

Incentives and disincentives to drug innovation: evidence from recent literature